Researcher Profile

Researcher Profile

Suzanne Merrill, MD

Suzanne Merrill, MD

Associate Professor, Department of Surgery
Division of Urology
Disease Teams:
Genitourinary Cancer
szm33@psu.edu

Research Interests

  • Neoplasms
  • Renal Cell Carcinoma
  • Recurrence
  • Therapeutics
  • Prostatic Neoplasms
  • Nephrectomy
  • Urinary Bladder Neoplasms
  • Mortality
  • Cystectomy
  • Prostatectomy
  • Survival
  • Guidelines

Clinical Trials

A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Patient perceptions regarding routine oncologic follow-up for urologic malignancies.
A Phase 2b, Single- Arm, Multicenter Trial to Evaluate the Effficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle- Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrance
Phase III Randomized Trial Of Concurrent Chemoradiotherapy With or Without Atezoluzumab in Localized Muscle Invasive Bladder Cancer
Phase 2 Study of Bladder-SparIng ChemoradiatioN with CIPosItive bladdeR cancEr (INSPIRE)EA8185
NRG-GU005 Phase III IGRT and SBRT VS IGRT and hypofractionated IMRT for localized intermediate risk prostate cancer
Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy
Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer EA8171

Recent Publications

2021

Grant Owens, R, Loloi, J, Lehman, EB, Kaag, MG, Raman, JD & Merrill, SB 2021, 'Is pelvic MRI imaging sufficient cross-sectional imaging for staging intermediate and high-risk prostate cancer?', Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2021.01.029

2020

Fuletra, JG, Watts, A, Kaag, MG, Lehman, E, Raman, JD & Merrill, SB 2020, 'Can preoperative imaging characteristics predict pT3 bladder cancer following cystectomy?', World Journal of Urology. https://doi.org/10.1007/s00345-020-03375-w
Merrill, SB 2020, 'EDITORIAL COMMENT', Urology, vol. 139, pp. 149-150. https://doi.org/10.1016/j.urology.2020.01.060
Li, H, Zhang, Q, Shuman, L, Kaag, M, Raman, JD, Merrill, S, DeGraff, DJ, Warrick, JI & Chen, G 2020, 'Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes', Scientific reports, vol. 10, no. 1, 1439. https://doi.org/10.1038/s41598-020-58351-6
Durant, AM, Lehman, E, Robyak, H, Merrill, SB, Kaag, MG & Raman, JD 2020, 'Hemostatic agent use during partial nephrectomy: trends, outcomes, and associated costs', International Urology and Nephrology, vol. 52, no. 11, pp. 2073-2078. https://doi.org/10.1007/s11255-020-02538-3
Loloi, J, Allen, JL, Schilling, A, Hollenbeak, C, Merrill, SB, Kaag, MG & Raman, JD 2020, 'In the World of Bladder Tumors: Size Does Matter', Bladder Cancer, vol. 6, no. 2, pp. 195-200. https://doi.org/10.3233/BLC-200273
Dreyfuss, LD, Master, VA, Raman, JD, Spiess, PE, Wells, SA, Merrill, SB, Peyton, CC, Sankar, D, Sohl, B, Patil, D, Shapiro, DD, Allen, GO & Abel, EJ 2020, 'Patterns of Initial Metastatic Recurrence After Surgery for High-Risk Nonmetastatic Renal Cell Carcinoma', Urology, vol. 146, pp. 152-157. https://doi.org/10.1016/j.urology.2020.07.045
Merrill, SB, Loloi, J, Schaefer, EW & Hollenbeak, CS 2021, 'Patterns of surveillance intensity in kidney cancer', International Urology and Nephrology, vol. 53, no. 3, pp. 447-453. https://doi.org/10.1007/s11255-020-02685-7

2019

Zaleski, M, Gogoj, A, Walter, V, Raman, JD, Kaag, M, Merrill, SB, Drabick, J, Joshi, M, Holder, S, DeGraff, DJ & Warrick, JI 2019, 'Mitotic activity in noninvasive papillary urothelial carcinoma: its value in predicting tumor recurrence and comparison with the contemporary 2-tier grading system', Human Pathology, vol. 84, pp. 275-282. https://doi.org/10.1016/j.humpath.2018.10.008

2018

Merrill, SB, Sohl, BS, Hamirani, A, Lehman, EB, Lehman, KK, Kaag, MG & Raman, JD 2019, 'Capturing Renal Cell Carcinoma Recurrences When Asymptomatic Improves Patient Survival', Clinical Genitourinary Cancer, vol. 17, no. 2, pp. 132-138. https://doi.org/10.1016/j.clgc.2018.11.009
Warrick, JI, Sjödahl, G, Kaag, M, Raman, JD, Merrill, S, Shuman, L, Chen, G, Walter, V & DeGraff, DJ 2019, 'Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants [Figure presented]', European Urology, vol. 75, no. 1, pp. 18-22. https://doi.org/10.1016/j.eururo.2018.09.003
Merrill, SB 2019, 'More Isn't Always Better: Time to Derive a Different Strategy for Renal Cell Carcinoma Surveillance', European Urology, vol. 75, no. 2, pp. 265-267. https://doi.org/10.1016/j.eururo.2018.10.052

2017

Joyce, DD, Psutka, SP, Groeschl, RT, Thompson, RH, Boorjian, SA, Cheville, JC, Merrill, S, Lohse, CM, Costello, BA, Que, FG & Leibovich, BC 2017, 'Complications and Outcomes Associated With Surgical Management of Renal Cell Carcinoma Involving the Liver: A Matched Cohort Study', Urology, vol. 99, pp. 155-161. https://doi.org/10.1016/j.urology.2016.08.015
Merrill, S, Boorjian, SA, Thompson, RH, Psutka, SP, Cheville, JC, Thapa, P, Tollefson, MK & Frank, I 2017, 'Oncologic surveillance following radical cystectomy: an individualized risk-based approach', World Journal of Urology, vol. 35, no. 12, pp. 1863-1869. https://doi.org/10.1007/s00345-017-2068-7
Merrill, S 2017, 'Postoperative Surveillance for Renal Cell Carcinoma', Urologic Clinics of North America, vol. 44, no. 2, pp. 313-323. https://doi.org/10.1016/j.ucl.2016.12.016
Psutka, SP, Heidenreich, M, Boorjian, SA, Bailey, GC, Cheville, JC, Stewart-Merrill, SB, Lohse, CM, Atwell, TD, Costello, BA, Leibovich, BC & Thompson, RH 2017, 'Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes', BJU International, vol. 119, no. 1, pp. 116-127. https://doi.org/10.1111/bju.13620

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)